Ixico Regulatory News (IXI)

IXICO plc

("IXICO" or the "Company")

Contract win for an early phase Multiple System Atrophy disease trial

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it has been selected by a leading global pharmaceutical company, and new client, to provide MRI imaging services for an early phase clinical trial in Multiple System Atrophy. IXICO has signed a start-up agreement with the client which is anticipated to extend to a contract value of approximately £0.6m early in 2023. The trial is expected to last for two years.

Since its inception, IXICO has built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders across the entire drug development lifecycle, from phase I through to commercialisation.

For further information please contact:

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews